The Surgeon’s Perspective on Neoadjuvant Chemoradiation for Rectal Cancer

  • Rhodri J. Codd
  • Peter M. Sagar


Pre-operative chemo-radiation has become standard practice in the treatment of patients with locally advanced rectal cancer. Indeed, in much of Europe and in the United States, pre-operative chemoradiation has been recommended as a standard of care for patients with clinical stage II and stage III rectal cancer. However, management philosophies for rectal cancer have evolved independently in different countries, with a number of varying approaches developing worldwide. The aim of this chapter is to review current practice and to provide an algorithm for the management of such patients.


Rectal cancer Chemo-radiation Down-staging Pathological response Complete response 


  1. 1.
    Glynne-Jones R, Harrison M, Hughes R. Challenges in the neoadjuvant treatment of rectal cancer: balancing the risk of recurrence and quality of life. Cancer Radiother. 2013;17(7):675–85.PubMedCrossRefGoogle Scholar
  2. 2.
    Heald RJ, Husband EM, Ryall RDH. The mesorectum in rectal cancer surgery – the clue to pelvic recurrence? Br J Surg. 1982;69:613–6.PubMedCrossRefGoogle Scholar
  3. 3.
    Heald RJ. The “Holy Plane” of rectal surgery. J R Soc Med. 1988;81:503–8.PubMedCentralPubMedGoogle Scholar
  4. 4.
    Heald RJ, Moran BJ, Ryall RD, et al. Rectal cancer: the Basingstoke experience of total mesorectal excision. Arch Surg. 1998;133:894–9.PubMedCrossRefGoogle Scholar
  5. 5.
    Kapiteijn E, Marijnen CAM, Nagtegaal ID, et al. Preoperative radiotherapy combined with total mesorectal excision for resectable rectal cancer. N Engl J Med. 2001;345:638–46.PubMedCrossRefGoogle Scholar
  6. 6.
    Cawthorn SJ, Parums DV, Gibbs NM, et al. Extent of mesorectal spread and involvement of lateral resection margin as prognostic factors after surgery for rectal cancer. Lancet. 1990;335:1055–9.PubMedCrossRefGoogle Scholar
  7. 7.
    Arbman G, Nilsson E, Hallbook O, Sjodahl R. Local recurrence following total mesorectal excision for rectal cancer. Br J Surg. 1996;83:375–9.PubMedCrossRefGoogle Scholar
  8. 8.
    Enker WE, Thaler HT, Cranor ML, Polyak T. Total mesorectal excision in the operative treatment of carcinoma of the rectum. J Am Coll Surg. 1995;181:335–46.PubMedGoogle Scholar
  9. 9.
    Arenas RB, Fichera A, Mhoon D, Michelassi F. Total mesorectal excision in the surgical treatment of rectal cancer: a prospective study. Arch Surg. 1998;133:608–11.PubMedCrossRefGoogle Scholar
  10. 10.
    Marr R, Birbeck K, Garvican J, Macklin CP, et al. The modern abdominoperineal excision: the next challenge after total mesorectal excision. Ann Surg. 2005;242(1):74–82.PubMedCentralPubMedCrossRefGoogle Scholar
  11. 11.
    Stelzner S, Holm T, Moran BJ, Heald RJ, et al. Deep pelvic anatomy revisited for a description of crucial steps in extralevator abdominoperineal excision for rectal cancer. Dis Colon Rectum. 2011;54(8):947–57.PubMedCrossRefGoogle Scholar
  12. 12.
    Huang A, Zhao H, Ling T, Quan Y, Zheng M, Feng B. Oncological superiority of extralevator abdominoperineal resection over conventional abdominoperineal resection: a meta-analysis. Int J Colorectal Dis. 2014;29:321–7.Google Scholar
  13. 13.
    Senapati A, O’Leary DP, Flashman KG, Parvaiz A, Thompson MR. Low rates of local recurrence after surgical resection of rectal cancer suggest a selective policy for preoperative radiotherapy. Colorectal Dis. 2012;14(7):838–43.PubMedCrossRefGoogle Scholar
  14. 14.
    Glynne-Jones R. Neoadjuvant treatment in rectal cancer: do we always need radiotherapy-or can we risk assess locally advanced rectal cancer better? Recent Results Cancer Res. 2012;196:21–36.PubMedCrossRefGoogle Scholar
  15. 15.
    Quirke P, Durdey P, Dixon MF, Williams NS. Local recurrence of rectal adenocarcinoma due to inadequate surgical resection. Histopathological study of lateral tumour spread and surgical excision. Lancet. 1986;2(8514):996–9.PubMedCrossRefGoogle Scholar
  16. 16.
    MERCURY Study Group. Extramural depth of tumor invasion at thin-section MR in patients with rectal cancer: results of the MERCURY study. Radiology. 2007;243(1):132–9.CrossRefGoogle Scholar
  17. 17.
    Kusters M, Marijnen CA, van de Velde CJ, et al. Patterns of local recurrence in rectal cancer; a study of the Dutch TME trial. Eur J Surg Oncol. 2010;36(5):470–6.PubMedCrossRefGoogle Scholar
  18. 18.
    National Collaborating Centre for Cancer (UK). Colorectal cancer: the diagnosis and management of colorectal cancer. NICE clinical guidelines, no. 131. Cardiff: National Collaborating Centre for Cancer (UK); 2011.Google Scholar
  19. 19.
    Chan AK, Wong A, Jenken D, Heine J, Buie D, Johnson D. Post treatment TNM staging is a prognostic indicator of survival and recurrence in tethered or fixed rectal carcinoma after preoperative chemotherapy and radiotherapy. Int J Radiat Oncol Biol Phys. 2005;61:665–77.PubMedCrossRefGoogle Scholar
  20. 20.
    Garcia-Aguilar J, Smith DD, Avila K, et al. Timing of Rectal Cancer Response to Chemoradiation Consortium. Optimal timing of surgery after chemoradiation for advanced rectal cancer: preliminary results of a multicenter, nonrandomized phase II prospective trial. Ann Surg. 2011;254:97–102.PubMedCentralPubMedCrossRefGoogle Scholar
  21. 21.
    de Campos-Lobato LF, Stocchi L, da Luz MA, et al. Pathologic complete response after neoadjuvant treatment for rectal cancer decreases distant recurrence and could eradicate local recurrence. Ann Surg Oncol. 2011;18:1590–8.PubMedCrossRefGoogle Scholar
  22. 22.
    Baker B, Salameh H, Al-Salman M, Daoud F. How does preoperative radiotherapy affect the rate of sphincter-sparing surgery in rectal cancer? Surg Oncol. 2012;21(3):e103–9.PubMedCrossRefGoogle Scholar
  23. 23.
    Sauer R, Becker H, Hohenberger W, et al. Preoperative versus postoperative chemoradiotherapy for rectal cancer. N Engl J Med. 2004;351(17):1731–40.PubMedCrossRefGoogle Scholar
  24. 24.
    Sloothaak DA, Geijsen DE, van Leersum NJ, Punt CJ, Buskens CJ, Bemelman WA, Tanis PJ. Optimal time interval between neoadjuvant chemoradiotherapy and surgery for rectal cancer. Br J Surg. 2013;100(7):933–9.PubMedCrossRefGoogle Scholar
  25. 25.
    Shihab OC, Taylor F, Salerno G, Heald RJ, Quirke P, Moran BJ, Brown G. MRI predictive factors for long-term outcomes of low rectal tumours. Ann Surg Oncol. 2011;18(12):3278–84.PubMedCrossRefGoogle Scholar
  26. 26.
    Francois Y, Nemoz CJ, Baulieux J, Vignal J, Grandjean JP, Partensky C, Souquet JC, Adeleine P, Gerard JP. Influence of the interval between preoperative radiation therapy and surgery on downstaging and on the rate of sphincter-sparing surgery for rectal cancer: the Lyon R90-01 randomized trial. J Clin Oncol. 1999;17(8):2396.PubMedGoogle Scholar
  27. 27.
    Kalady MF, de Campos-Lobato LF, Stocchi L, Geisler DP, Dietz D, Lavery IC, Fazio VW. Predictive factors of pathologic complete response after neoadjuvant chemoradiation for rectal cancer. Ann Surg. 2009;250(4):582–9.PubMedGoogle Scholar
  28. 28.
    de Campos-Lobato LF, Geisler DP, da Luz MA, Stocchi L, Dietz D, Kalady MF. Neoadjuvant therapy for rectal cancer: the impact of longer interval between chemoradiation and surgery. J Gastrointest Surg. 2011;15(3):444–50.PubMedCrossRefGoogle Scholar
  29. 29.
    Dhadda AS, Zaitoun AM, Bessell EM. Regression of rectal cancer with radiotherapy with or without concurrent capecitabine–optimising the timing of surgical resection. Clin Oncol (R Coll Radiol). 2009;21(1):23–31.CrossRefGoogle Scholar
  30. 30.
    Maas M, Nelemans PJ, Valentini V, Das P, et al. Long-term outcome in patients with a pathological complete response after chemoradiation for rectal cancer: a pooled analysis of individual patient data. Lancet Oncol. 2010;11(9):835–44.PubMedCrossRefGoogle Scholar
  31. 31.
    Martin ST, Heneghan HM, Winter DC. Systematic review and meta-analysis of outcomes following pathological complete response to neoadjuvant chemoradiotherapy for rectal cancer. Br J Surg. 2012;99(7):918–28.Google Scholar
  32. 32.
    Callender GG, Das P, Rodriguez-Bigas MA, Skibber JM, Crane CH, Krishnan S, Delclos ME, Feig BW. Local excision after preoperative chemoradiation results in an equivalent outcome to total mesorectal excision in selected patients with T3 rectal cancer. Ann Surg Oncol. 2010;17(2):441–7.PubMedCentralPubMedCrossRefGoogle Scholar
  33. 33.
    Lezoche E, Guerrieri M, Paganini AM, Baldarelli M, De Sanctis A, Lezoche G. Long-term results in patients with T2-3N0 distal rectal cancer undergoing radiotherapy before transanal endoscopic microsurgery. Br J Surg. 2005;92(12):1546–52.PubMedCrossRefGoogle Scholar
  34. 34.
    Nair RM, Siegel EM, Chen DT, Fulp WJ, Yeatman TJ, Malafa MP, Marcet J, Shibata D. Long-term results of transanal excision after neoadjuvant chemoradiation for T2 and T3 adenocarcinomas of the rectum. J Gastrointest Surg. 2008;12(10):1797–805.PubMedCrossRefGoogle Scholar
  35. 35.
    Kim CJ, Yeatman TJ, Coppola D, Trotti A, Williams B, Barthel JS, Dinwoodie W, Karl RC, Marcet J. Local excision of T2 and T3 rectal cancers after downstaging chemoradiation. Ann Surg. 2001;234(3):352–8; discussion 358–9.PubMedCentralPubMedCrossRefGoogle Scholar
  36. 36.
    Habr-Gama A, Perez RO, Nadalin W, Sabbaga J, et al. Operative versus nonoperative treatment for stage 0 distal rectal cancer following chemoradiation therapy: long-term results. Ann Surg. 2004;240(4):711–7; discussion 717–8.PubMedCentralPubMedGoogle Scholar
  37. 37.
    Habr-Gama A, de Souza PM, Ribeiro U, Nadalin W, Gansl R, Sousa Jr AH, et al. Low rectal cancer: impact of radiation and chemotherapy on surgical treatment. Dis Colon Rectum. 1998;41:1087–96.PubMedCrossRefGoogle Scholar
  38. 38.
    Habr-Gama A, de Souza PM, Ribeiro U. Multimodality therapy in low rectal cancer: long-term outcome of complete responders. Dis Colon Rectum. 2001;44:A18.CrossRefGoogle Scholar
  39. 39.
    Habr-Gama A, Perez RO, Nadalin W, Nahas SC, Ribeiro Jr U, Silva E, Sousa Jr AH, et al. Long term results of preoperative chemoradiation for distal rectal cancer: correlation between final stage and survival. J Gastrointest Surg. 2005;9:90–109.PubMedCrossRefGoogle Scholar
  40. 40.
    Habr-Gama A, Perez RO, Proscurshim I, Campos FG, Nadalin W, Kiss D, et al. Patterns of failure and survival for non-operative treatment of stage c0 distal rectal cancer following neoadjuvant chemoradiation therapy. J Gastrointest Surg. 2006;10:1319–28.PubMedCrossRefGoogle Scholar
  41. 41.
    Habr-Gama A. Assessment and management of the complete clinical response of rectal cancer to chemoradiotherapy. Colorectal Dis. 2006;8 Suppl 3:21–4.PubMedCrossRefGoogle Scholar
  42. 42.
    Habr-Gama A, Perez RO, Wynn G, Marks J, Kessler H, Gama-Rodrigues J. Complete clinical response after neoadjuvant chemoradiation therapy for distal rectal cancer: characterization of clinical and endoscopic findings for standardization. Dis Colon Rectum. 2010;53:1692–8.PubMedCrossRefGoogle Scholar
  43. 43.
    Perez RO, Habr-Gama A, Pereira GV, Lynn PB, Alves PA, Proscurshim I, Rawet V, Gama-Rodrigues J. Role of biopsies in patients with residual rectal cancer following neoadjuvant chemoradiation after downsizing: can they rule out persisting cancer? Colorectal Dis. 2012;14(6):714–20.PubMedCrossRefGoogle Scholar
  44. 44.
    Perez RO, Habr-Gama A, Gama-Rodrigues J, Proscurshim I, et al. Accuracy of positron emission tomography/computed tomography and clinical assessment in the detection of complete rectal tumor regression after neoadjuvant chemoradiation: long-term results of a prospective trial (National Clinical Trial 00254683). Cancer. 2012;118(14):3501–11.PubMedCrossRefGoogle Scholar
  45. 45.
    Maas M, Beets-Tan RG, Lambregts DM, Lammering G, Nelemans PJ, et al. Wait-and-see policy for clinical complete responders after chemoradiation for rectal cancer. J Clin Oncol. 2011;29(35):4633–40.PubMedCrossRefGoogle Scholar
  46. 46.
    Wynn GR, Bhasin N, Macklin CP, George ML. Complete clinical response to neoadjuvant chemoradiotherapy in patients with rectal cancer: opinions of British and Irish specialists. Colorectal Dis. 2010;12(4):327–33.PubMedCrossRefGoogle Scholar
  47. 47.
    Bedrosian I, Rodriguez-Bigas MA, Feig B, et al. Predicting the node-negative mesorectum after preoperative chemoradiation for locally advanced rectal carcinoma. J Gastrointest Surg. 2004;8(1):56–62; discussion 62–3.PubMedCrossRefGoogle Scholar
  48. 48.
    Glynne-Jones R, Hughes R. Critical appraisal of the ‘wait and see’ approach in rectal cancer for clinical complete responders after chemoradiation. Br J Surg. 2012;99(7):897–909.PubMedCrossRefGoogle Scholar
  49. 49.
    Loos M, Quentmeier P, Schuster T, Nitsche U, et al. Effect of preoperative radio(chemo)therapy on long-term functional outcome in rectal cancer patients: a systematic review and meta-analysis. Ann Surg Oncol. 2013;20(6):1816–28.PubMedCrossRefGoogle Scholar
  50. 50.
    Stumpf M, Junge K, Wendlandt M, Krones C, et al. Risk factors for anastomotic leakage after colorectal surgery. Zentralbl Chir. 2009;134(3):242–8.PubMedCrossRefGoogle Scholar
  51. 51.
    Sebag-Montefiore D, Stephens RJ, Steele R, et al. Preoperative radiotherapy versus selective postoperative chemoradiotherapy in patients with rectal cancer (MRC CR07 and NCIC-CTG C016): a multicentre, randomised trial. Lancet. 2009;373:811–20.PubMedCentralPubMedCrossRefGoogle Scholar
  52. 52.
    Artioukh DY, Smith RA, Gokul K. Risk factors for impaired healing of the perineal wound after abdominoperineal resection of rectum for carcinoma. Colorectal Dis. 2007;9(4):362–7.PubMedCrossRefGoogle Scholar
  53. 53.
    De Caluwé L, Van Nieuwenhove Y, Ceelen WP. Preoperative chemoradiation versus radiation alone for stage II and III resectable rectal cancer. Cochrane Database Sys Rev. 2013;(2):CD006041. doi: 10.1002/14651858.CD006041.pub3.
  54. 54.
    Bosset JF, Collette L, Calais G, et al. Chemotherapy with preoperative radiotherapy in rectal cancer. N Engl J Med. 2006;355:1114–23.PubMedCrossRefGoogle Scholar
  55. 55.
    Bujko K, Nowacki MP, Nasierowska-Guttmejer A, Michalski W, Bebenek M, Kryj M. Long-term results of a randomized trial comparing preoperative short-course radiotherapy with preoperative conventionally fractionated chemoradiation for rectal cancer. Br J Surg. 2006;93:1215–23.PubMedCrossRefGoogle Scholar
  56. 56.
    Peeters KC, van de Velde CJ, Leer JW, et al. Late side effects of short-course preoperative radiotherapy combined with total mesorectal excision for rectal cancer: increased bowel dysfunction in irradiated patients–a Dutch colorectal cancer group study. J Clin Oncol. 2005;23:6199–206.PubMedCrossRefGoogle Scholar
  57. 57.
    Fleming FJ, Påhlman L, Monson JR. Neoadjuvant therapy in rectal cancer. Dis Colon Rectum. 2011;54(7):901–12.PubMedCrossRefGoogle Scholar
  58. 58.
    Adams E, Boulton MG, Horne A, Rose PW, et al. The effects of pelvic radiotherapy on cancer survivors: symptom profile, psychological morbidity and quality of life. Clin Oncol (R Coll Radiol). 2014;26(1):10–7.CrossRefGoogle Scholar

Copyright information

© Springer-Verlag London 2015

Authors and Affiliations

  1. 1.The John Goligher Department of Colorectal SurgerySt. James’s University HospitalLeedsUK

Personalised recommendations